A Phase 1/Phase 2a study of MDI-0151 in various refractory inflammatory diseases caused by excessive activation of neutrophils
Latest Information Update: 28 Jun 2024
At a glance
- Drugs MDI 0151 (Primary)
- Indications Inflammation
- Focus Adverse reactions
Most Recent Events
- 28 Jun 2024 New trial record
- 21 Jun 2024 According to a Melodia Therapeutics and Alivexis media release, company will rapidly initiate IND-enabling activities for MDI-0151 to prepare for a Phase 1/Phase 2a study in various refractory inflammatory diseases caused by excessive activation of neutrophils, such as ANCA-associated Vasculitis and several other relevant diseases in the context of neutrophils.